7 results on '"Hiwasa, Takaki"'
Search Results
2. Novel serum autoantibodies against ß-actin (ACTB) in amyotrophic lateral sclerosis.
- Author
-
Sugimoto, Kazuo, Mori, Masahiro, Liu, Jia, Shibuya, Kazutomo, Isose, Sagiri, Koide, Mizuho, Hiwasa, Takaki, and Kuwabara, Satoshi
- Subjects
AMYOTROPHIC lateral sclerosis ,AUTOANTIBODIES ,COMPLEMENTARY DNA ,PARKINSON'S disease ,BIOMARKERS - Abstract
To identify novel biomarkers using the serological analysis of recombinant cDNA expression libraries (SEREX) method and to evaluate their clinical significance in amyotrophic lateral sclerosis (ALS). Serum of ALS patients were screened for autoantibodies using the SEREX method. The identified autoantibodies were validated by measuring their serum levels in 70 ALS patients, 60 normal controls (NC), and 62 Parkinson disease (PD) patients using the amplified luminescent proximity homogeneous assay-linked immunosorbent assay (AlphaLISA). The clinical relevance of these autoantibodies was investigated in ALS patients. SEREX identified 16 candidate antigens including β-actin (ACTB) in addition to proteasome subunit alpha type 7 (PSMA7) that we previously reported, and serum levels of antibodies against ACTB, were significantly higher in ALS patients than in NC (p < 0.001) and PD patients (p = 0.001). Moreover, serum levels of anti-ACTB antibody were higher in advanced stage ALS patients (Stage 4 on the King's ALS clinical staging) and in those with more severe disability (ALS Functional Rating Scale revised [ALSFRS-R] score < 40.5) compared to early stage (Stage 2 [2nd region involved)]) patients and those with less severe disability (ALSFRS-R score ≥ 40.5) (p = 0.003, p = 0.014). Anti-ACTB antibody levels were also negatively correlated with ALSFRS-R score (ρ = −0.409, p = 0.001), but positively correlated with clinical disease stage (ρ = 0.355, p = 0.003), and showed a weak positive correlation with disease duration (ρ = 0.294, p = 0.014). Anti-ACTB antibodies may be a potential biomarker of ALS could indicate disease severity. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
3. Novel autoantibodies against the proteasome subunit PSMA7 in amyotrophic lateral sclerosis.
- Author
-
Sugimoto, Kazuo, Hiwasa, Takaki, Shibuya, Kazutomo, Hirano, Shigeki, Beppu, Minako, Isose, Sagiri, Arai, Kimihito, Takiguchi, Masaki, Kuwabara, Satoshi, and Mori, Masahiro
- Subjects
- *
AMYOTROPHIC lateral sclerosis , *AUTOIMMUNITY , *AUTOANTIBODIES , *IMMUNOGLOBULINS , *GENE expression - Abstract
Abstract Objective To identify autoantibodies using sera from ALS patients and elucidate their roles in disease pathology. Methods An immunological screening was performed with a phage expression library SEREX method using sera from 3 ALS patients to identify ALS-related autoantibodies. Levels of antibodies identified by SEREX were measured in 33 ALS patients and 30 normal controls (NCs) by AlphaLISA using recombinant non-full-length proteins. The results were then validated by ELISA using full-length proteins in 71 ALS patients, 30 NCs and 34 disease controls (DCs). The relationship between the titres and clinical profiles of ALS patients were examined. Results Four autoantibodies identified by SEREX were proteasome subunit alpha type 7 (PSMA7), vimentin, hydroxymethylbilane synthase and TBC1 domain family member 2 (TBC1D2). AlphaLISA revealed that only the anti-PSMA7 and anti-TBC1D2 levels were significantly different between the ALS and NCs groups. ELISA showed that only the levels of antibody against PSMA7, involved in protein degradation by the ubiquitin-proteasome pathway (UPP), were higher in the ALS group than both the NC (P <.01) and DC (P =.034) groups. Anti-PSMA7 levels tended to be negatively correlated with the logarithm of disease duration (P =.052) and were significantly positively correlated with the logarithm of creatine kinase levels (P =.011). The anti-PSMA7 antibody levels were different between patients with and without dysphagia (P <.01). Conclusions: Serum anti-PSMA7 antibody might be a disease-promoting factor in early-stage ALS and might be a biomarker of ALS. Anti-PSMA7 autoantibody might contribute to the pathogenesis of ALS, possibly via its role in the UPP. Graphical abstract Unlabelled Image Highlights • We identified antibodies against PSMA7 in sera from ALS patients by SEREX. • SEREX is an ideal method for identifying antigens of patients with motor neuron diseases and other immune-related diseases. • The titres were apparently higher in ALS patients than in normal controls and diseases controls. • Anti-PSMA7 autoantibody might contribute to the pathogenesis of ALS, possibly via its role in the UPP. • Serum anti-PSMA7 antibody might be a disease-promoting factor in early-stage ALS and might be a biomarker of ALS. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
4. Serum WT1-271 IgM antibody as a novel diagnostic marker for Gastric Cancer.
- Author
-
Ito, Masaaki, Oji, Yusuke, Adachi, Mayuko, Imanishi, Rin, Alzaaqi, Shouq, Hiwasa, Takaki, Oshima, Yoko, Yajima, Satoshi, Suzuki, Takashi, Nanami, Tatsuki, Sumazaki, Makoto, Shiratori, Fumiaki, Funahashi, Kimihiko, Sugiayama, Haruo, and Shimada, Hideaki
- Subjects
IMMUNOGLOBULIN M ,TUMOR markers ,STOMACH cancer ,RECEIVER operating characteristic curves ,PEPTIDES ,IMMUNOGLOBULINS - Abstract
The Wilms tumor 1 gene, WT1, is overexpressed in various types of cancer, including gastric cancer. The product of WT1 is highly immunogenic and is a promising target molecule for cancer immunotherapy. The current study aimed to examine the production of WT1-specific IgG and IgM autoantibodies to identify biomarkers of diagnostic value in patients with gastric cancer. IgG antibodies that bind to WT1-derived peptides were obtained, the serum levels of which correlate with those of IgG antibodies against the WT1 protein in patients with intestinal malignancies. The serum levels of IgG and IgM antibodies against the WT1-271 peptide (271-288 amino acids) were examined in 39 healthy individuals and 97 patients with gastric cancer. The positivity cutoff value was determined according to the receiver operating characteristic curve. The association between WT1-271 IgM and the clinicopathological factors and prognosis of patients was additionally analyzed. The results revealed that serum WT1-271 IgM antibody levels in patients with gastric cancer were significantly higher than those in healthy individuals. The sensitivity and specificity of this antibody for gastric cancer were 67.0 and 71.8%, respectively; this sensitivity was improved when compared with conventional tumor markers (P<0.001). There was no statistical difference in WT1-271 IgG antibody levels between patients with gastric cancer and healthy individuals. Serum WT1-271 IgM antibody levels were not significantly associated with clinicopathological factors but were associated with unfavorable prognosis. Serum WT1-271 IgM antibody levels could serve as a diagnostic biomarker in patients with gastric cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
5. Identification of serum anti-striatin 4 antibodies as a common marker for esophageal cancer and other solid cancers.
- Author
-
Ito, Masaaki, Hiwasa, Takaki, Oshima, Yoko, Yajima, Satoshi, Suzuki, Takashi, Nanami, Tatsuki, Sumazaki, Makoto, Shiratori, Fumiaki, Funahashi, Kimihiko, Takizawa, Hirotaka, Kashiwado, Koichi, Tochigi, Naobumi, and Shimada, Hideaki
- Subjects
- *
ESOPHAGEAL cancer , *TUMOR markers , *CANCER prognosis , *IMMUNOGLOBULINS , *COLORECTAL cancer , *ONCOLOGIC surgery , *LUMINESCENCE - Abstract
Solid cancers have a poor prognosis, and their morbidity and mortality after surgery is high. Even after radical surgery for esophageal cancer, there have been cases of early postoperative death. The present study therefore aimed to explore new tumor markers that can predict the early postoperative prognosis. To identify antibody markers, serological antigens were identified using recombinant cDNA expression cloning (SEREX). The results identified striatin 4 (STRN4) as the antigen recognized by serum IgG antibodies in patients with esophageal cancer. After performing an amplified luminescence proximity homogeneous assay-linked immunosorbent assay (AlphaLISA), it was revealed that when compared with healthy donors, serum anti-STRN4 antibody (STRN4-Ab) levels were significantly higher not only in patients with esophageal cancer but also to lesser extent, in those with gastric cancer, colorectal cancer, lung cancer and breast cancer. Compared with STRN4-Ab-negative patients with esophageal cancer, STRN4-Ab-positive patients had a poorer postoperative prognosis at early stages, suggesting that STRN4-Abs may be useful for predicting poor early-stage prognoses of patients with esophageal cancer. The positive diagnosis rates of esophageal cancer using the STRN4-Ab marker and conventional markers, including squamous cell carcinoma antigen and p53 antibody alone, were 26.4, 35.2 and 19.1% respectively; a result that increased up to 59.1% by combining all three markers. Serum STRN4-Ab may serve as a novel marker of esophageal cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
6. Circulating Anti-Sorting Nexins 16 Antibodies as an Emerging Biomarker of Coronary Artery Disease in Patients with Obstructive Sleep Apnea.
- Author
-
Katsumata, Yusuke, Terada, Jiro, Matsumura, Takuma, Koshikawa, Ken, Sakao, Seiichiro, Tomiyoshi, Go, Shinmen, Natsuko, Nakamura, Rika, Kuroda, Hideyuki, Nagashima, Kengo, Kobayashi, Yoshio, Kobayashi, Eiichi, Iwadate, Yasuo, Zhang, Xiao-Meng, Hiwasa, Takaki, and Tatsumi, Koichiro
- Subjects
SLEEP apnea syndromes ,CORONARY disease ,ACUTE coronary syndrome ,CARDIOVASCULAR diseases risk factors ,LOGISTIC regression analysis ,DYSLIPIDEMIA - Abstract
Biomarkers are not available for monitoring the onset and progression of coronary artery disease (CAD) in patients with obstructive sleep apnea (OSA), a major risk factor for arteriosclerotic cardiovascular diseases. This study aimed to test for correlation between circulating anti-Sorting Nexins 16 antibody (SNX16-Ab) levels, CAD history and clinical parameters of patients with OSA. Sixty-four healthy donors, 82 adults with OSA, and 96 with acute coronary syndrome (ACS) were studied. Serum samples were collected at diagnostic polysomnography in the OSA group or at the disease onset in the ACS group. Serum SNX16-Ab levels were measured by amplified luminescence proximity homogeneous assay (AlphaLISA), and correlation between SNX16-Ab levels and clinical parameters was analyzed. SNX16-Ab levels and apnea-hypopnea index (AHI) were weakly correlated. Additionally, logistic regression analyses of OSA group identified that elevated SNX16-Ab level associated with the history of CAD. Circulating SNX16-Ab could increase during CAD pathogenesis in patients with OSA. Further prospective studies are required to prove the predictive potential of SNX16-Ab level in CAD onset of patients with OSA. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
7. Nardilysin is a promising biomarker for the early diagnosis of acute coronary syndrome.
- Author
-
Chen, Po-Min, Ohno, Mikiko, Hiwasa, Takaki, Nishi, Kiyoto, Saijo, Sayaka, Sakamoto, Jiro, Morita, Yusuke, Matsuda, Shintaro, Watanabe, Shin, Kuwabara, Yasuhide, Ono, Koh, Imai, Masao, Inoue, Katsumi, Murai, Tatsuya, Inada, Tsukasa, Tanaka, Masaru, Kita, Toru, Kimura, Takeshi, and Nishi, Eiichiro
- Subjects
- *
ACUTE coronary syndrome , *BIOMARKERS , *AUTOANTIBODIES , *METALLOENDOPEPTIDASES , *BLOOD serum analysis , *DIAGNOSIS - Abstract
Background Biomarkers for detection of transient myocardial ischemia in patients with unstable angina (UA) or for very early diagnosis of acute myocardial infarction (AMI) are not currently available. Methods and results We performed two sequential screenings of autoantibodies elevated shortly after the onset of acute coronary syndrome (ACS), and focused on metalloendopeptidase nardilysin (NRDC) among 19 identified candidate antigens. In a retrospective analysis among 93 ACS and 117 non-ACS patients, the serum level of NRDC was significantly increased in patients with ACS compared with that in patients with non-ACS (2073.5 ± 189.8 pg/ml versus 775.7 ± 63.4 pg/ml, P < 0.0001). The area under the curve of NRDC for the diagnosis of ACS was 0.822 by the receiver operating characteristic curves analysis. In the time course analysis in 43 consecutive ACS patients (AMI: N = 35 and UA: N = 8), serum concentration of NRDC was significantly increased even in UA patients with a peak serum NRDC levels reached at admission both in AMI and UA patients. In a mouse model of AMI, we found an acute increase in serum NRDC and reduced NRDC expression in ischemic regions shortly after coronary artery ligation. NRDC expression was also reduced in infarcted regions in human autopsy samples from AMI patients. Moreover, the short treatment of primary culture of rat cardiomyocytes with H 2 O 2 or A23187 induced NRDC secretion without cell toxicity. Conclusion NRDC is a promising biomarker for the early detection of ACS, even in UA patients without elevation of necrosis markers. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.